Correction to: Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review

Dongzhe Hong; Lei Si; Minghuan Jiang; Hui Shao; Wai-kit Ming; Yingnan Zhao; Yan Li; Lizheng Shi

doi:10.1007/s40273-019-00833-1

Correction to: Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review

Dongzhe Hong
, Lei Si
, Minghuan Jiang
, Hui Shao
, Wai-kit Ming
, Yingnan Zhao
, Yan Li
, Lizheng Shi^*

^*Corresponding author for this work

Research output: Journal Publications and Reviews › Erratum

6 Citations (Scopus)

Abstract

Correction to: PharmacoEconomics (2019) 37:777–818
https://doi.org/10.1007/s40273-019-00774-9

The term “CORE diabetes model” was used throughout the article for consistency. However, there is variation in referencing the original “CORE diabetes model” in the literature [1]: among a total of 37 relevant cost-effectiveness analysis studies published from 2007 to 1 June 2018, 13 studies referenced the model as the “CORE Diabetes Model”, 21 as the “IMS CORE Diabetes Model”, two as the “QuintilesIMS Health CORE Diabetes Model”, and one as the “IQVIA CORE Diabetes Model”. The existence in the literature of multiple names for this model is due to company mergers. For clarification, since 2017 this model has officially been called the “IQVIA CORE Diabetes Model”.

Original language	English
Pages (from-to)	1553
Journal	PharmacoEconomics
Volume	37
Issue number	12
Online published	4 Sept 2019
DOIs	https://doi.org/10.1007/s40273-019-00833-1
Publication status	Published - Dec 2019
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access Output

10.1007/s40273-019-00833-1

Other Access Options

Check CityUHK Library

Permanent Link

Right click to copy link

Fingerprint

Dive into the research topics of 'Correction to: Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review'. Together they form a unique fingerprint.

6 Scopus Citations
1 RGC 21 - Publication in refereed journal

Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review
Hong, D., Si, L., Jiang, M., Shao, H., Ming, W.-K., Zhao, Y., Li, Y. & Shi, L., 1 Jun 2019, In: PharmacoEconomics. 37, 6, p. 777-818
Research output: Journal Publications and Reviews › RGC 21 - Publication in refereed journal › peer-review
56 Link opens in a new tab Citations (Scopus)

Cite this

@article{3358eae668314669b80e9d9cebab2268,

title = "Correction to: Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review",

abstract = "Correction to: PharmacoEconomics (2019) 37:777–818 https://doi.org/10.1007/s40273-019-00774-9 The term “CORE diabetes model” was used throughout the article for consistency. However, there is variation in referencing the original “CORE diabetes model” in the literature [1]: among a total of 37 relevant cost-effectiveness analysis studies published from 2007 to 1 June 2018, 13 studies referenced the model as the “CORE Diabetes Model”, 21 as the “IMS CORE Diabetes Model”, two as the “QuintilesIMS Health CORE Diabetes Model”, and one as the “IQVIA CORE Diabetes Model”. The existence in the literature of multiple names for this model is due to company mergers. For clarification, since 2017 this model has officially been called the “IQVIA CORE Diabetes Model”.",

author = "Dongzhe Hong and Lei Si and Minghuan Jiang and Hui Shao and Wai-kit Ming and Yingnan Zhao and Yan Li and Lizheng Shi",

year = "2019",

month = dec,

doi = "10.1007/s40273-019-00833-1",

language = "English",

volume = "37",

pages = "1553",

journal = "PharmacoEconomics",

issn = "1170-7690",

publisher = "Adis International Ltd",

number = "12",

}

Hong, D, Si, L, Jiang, M, Shao, H, Ming, W, Zhao, Y, Li, Y & Shi, L 2019, 'Correction to: Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review', PharmacoEconomics, vol. 37, no. 12, pp. 1553. https://doi.org/10.1007/s40273-019-00833-1

Correction to: Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review. / Hong, Dongzhe; Si, Lei; Jiang, Minghuan et al.
In: PharmacoEconomics, Vol. 37, No. 12, 12.2019, p. 1553.

Research output: Journal Publications and Reviews › Erratum

TY - JOUR

T1 - Correction to: Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review

AU - Hong, Dongzhe

AU - Si, Lei

AU - Jiang, Minghuan

AU - Shao, Hui

AU - Ming, Wai-kit

AU - Zhao, Yingnan

AU - Li, Yan

AU - Shi, Lizheng

PY - 2019/12

Y1 - 2019/12

N2 - Correction to: PharmacoEconomics (2019) 37:777–818 https://doi.org/10.1007/s40273-019-00774-9 The term “CORE diabetes model” was used throughout the article for consistency. However, there is variation in referencing the original “CORE diabetes model” in the literature [1]: among a total of 37 relevant cost-effectiveness analysis studies published from 2007 to 1 June 2018, 13 studies referenced the model as the “CORE Diabetes Model”, 21 as the “IMS CORE Diabetes Model”, two as the “QuintilesIMS Health CORE Diabetes Model”, and one as the “IQVIA CORE Diabetes Model”. The existence in the literature of multiple names for this model is due to company mergers. For clarification, since 2017 this model has officially been called the “IQVIA CORE Diabetes Model”.

AB - Correction to: PharmacoEconomics (2019) 37:777–818 https://doi.org/10.1007/s40273-019-00774-9 The term “CORE diabetes model” was used throughout the article for consistency. However, there is variation in referencing the original “CORE diabetes model” in the literature [1]: among a total of 37 relevant cost-effectiveness analysis studies published from 2007 to 1 June 2018, 13 studies referenced the model as the “CORE Diabetes Model”, 21 as the “IMS CORE Diabetes Model”, two as the “QuintilesIMS Health CORE Diabetes Model”, and one as the “IQVIA CORE Diabetes Model”. The existence in the literature of multiple names for this model is due to company mergers. For clarification, since 2017 this model has officially been called the “IQVIA CORE Diabetes Model”.

UR - https://www.scopus.com/pages/publications/85071765081

UR - https://www.scopus.com/record/pubmetrics.uri?eid=2-s2.0-85071765081&origin=recordpage

U2 - 10.1007/s40273-019-00833-1

DO - 10.1007/s40273-019-00833-1

M3 - Erratum

C2 - 31485924

SN - 1170-7690

VL - 37

SP - 1553

JO - PharmacoEconomics

JF - PharmacoEconomics

IS - 12

ER -

Correction to: Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review

Abstract

UN SDGs

Access Output

Other Access Options

Permanent Link

Other Files and Links

Fingerprint

Research output

Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review

Cite this